Brief: Hansa Biopharma Reports Positive Efficacy, Safety Results From Study
27/05/2026 06:15
BRIEF-Hansa Biopharma Reports Positive Efficacy, Safety Results From Study May 27 (Reuters) - Hansa Biopharma AB HNSA.ST:
HANSA BIOPHARMA REPORTS POSITIVE EFFICACY AND SAFETY RESULTS FROM IDEFIRIX[®] EUROPEAN POST AUTHORIZATION STUDY IN KIDNEY TRANSPLANTATION
REPORTS 90% 1-YEAR GRAFT FAILURE-FREE SURVIVAL IN PAES STUDY
IDEFIRIX GENERALLY WELL TOLERATED WITH CONSISTENT SAFETY PROFILE
PLANS EMA SUBMISSION FOR FULL MARKETING AUTHORIZATION IN Q4 2026
Source text: ID:nWkr8TFphf
Further company coverage: HNSA.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com;))
Recent news on Hansa Biopharma AB
See all newsBrief: Hansa Biopharma Q3 Rev Up At SEK 143 Mln
Sweden's Hansa Biopharma Q3 revenue surges on SERB license deal
Brief: Hansa Biopharma Q3 Net Income SEK -178.5 Million
Brief: Hansa Biopharma Announces Positive Idefirix Paes Results Presented In The High-Impact Clinical Trials Session At Asn Kidney Week
Brief: Hansa Biopharma Submits IND Application To FDA For HNSA-5487 In GBS